Answers are grounded in this paper and cite their sources.
Concern about the venous thromboembolism (VTE) risk of new hormonal contraceptive options shortly after their entry into the market has triggered a number of 'pill scares', each of which resulted in panic stopping of the formulations in question and a spike in unplanned pregnancies, yet with no subsequent reduction in VTE rates among women of reproductive age.
No takes yet. Share an insight, caveat, or question.
Reid et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: